Company Overview and News

Regeneus director supports stem cell technology through on-market purchase

Regeneus Ltd's (ASX:RGS) recently appointed Japanese-based non-executive director, Leo Lee, has demonstrated his confidence in the company’s stem cell technology platform through an on-market purchase of shares.
Upvote Downvote

Regeneus has positive Progenza trial results published in respected medical journal

Regeneus Ltd (ASX:RGS) has had the positive results from a phase I safety trial of Progenza in patients with knee osteoarthritis validated by publication in a respected medical journal.
Upvote Downvote

Regeneus’ near-term focus on licensing osteoarthritis treatment in Japan

Regeneus Ltd (ASX:RGS) is placing its primary near-term focus on licensing the Progenza treatment for osteoarthritis in Japan.
Upvote Downvote

Regeneus takes step towards bringing Progenza osteoarthritis treatment to Europe

Regeneus Ltd (ASX:RGS) has taken a step towards bringing its Progenza osteoarthritis treatment to Europe after being granted Advanced Therapy Medicinal Product (ATMP) designation.
Upvote Downvote

Regeneus granted key cancer treatment patent in Japan

Regeneus Ltd (ASX:RGS) has been granted a key patent in Japan covering the use of cancer vaccine technology for treatment of a range of cancers in humans and animals.
Upvote Downvote

Regeneus shares rise as results show Sygenus gel successfully fights acne

Regeneus Ltd (ASX:RGS) has received promising results indicating that the topical use of Sygenus gel for six weeks in adults with acne was well tolerated.
Upvote Downvote

Regeneus appoints experienced pharmaceutical executive to board

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company has appointed Leo Lee as an independent non-executive director with effect from December.
Upvote Downvote

Regeneus finds impressive pain relief properties in Sygenus

Regeneus (ASX:RGS) has revealed study results that highlight its Sygenus technology as showing a more potent and longer lasting effect on pain than morphine.
Upvote Downvote

Regeneus Ltd granted acne patent in U.S. for Sygenus

Regeneus Ltd (ASX:RGS) has been issued a notice of allowance by the United States Patent Office for a patent related to Sygenus for the treatment of acne.
Upvote Downvote

Regeneus Ltd receives milestone payment to cap off quarter

Regeneus Ltd (ASX:RGS) received its US$1 million milestone payment on June 30, 2017 for meeting the primary endpoints of its Phase 1 safety trial of Progenza in patients with knee osteoarthritis.
Upvote Downvote

Regeneus to receive cash payment for trial success

Regeneus (ASX:RGS) is set to receive a milestone payment of US$1 million for meeting the primary endpoints of its Phase 1 safety trial of Progenza in patients with knee osteoarthritis.
Upvote Downvote

Regeneus: Access latest PPT from Proactive's CEO Sessions

Regeneus (ASX:RGS) chief executive officer, John Martin, joined Proactive's CEO Sessions in Sydney on Wednesday 14th June and Melbourne on Thursday 15th June.
Upvote Downvote

XTEK brings Homeland Security Solutions to Proactive's Spotlight CEO Sessions

The company provides a wide range of specialised products in the areas of Explosive Ordinance Disposal, Unmanned Aerial Systems and imagery, weapons/ballistic protection.
Upvote Downvote

AuKing Mining delivers Mexican gold-silver to Proactive's CEO Sessions

AuKing Mining (ASX:AKN) has undergone a transformation change by acquiring an interest in a high-grade gold-silver project in Mexico.
Upvote Downvote

Pioneer Resources brings demand driven commodities to Proactive's CEO Sessions

Pioneer Resources (ASX:PIO) holds a portfolio of projects in Australian and Canada which are prospective for key global demand-driven commodities.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...